The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Liadov K.V.

Lechebno-reabilitatsionnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Rerberg A.G.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kozyrin I.A.

Klinika khirurgii i onkologii Lechebno-reabilitatsionnogo tsentra Minzdrava RF, Moskva

Lyadov V.K.

Medical and Rehabilitation Center under the Ministry of Health of Russian Federation, Moscow, Russia

Maiorov K.V.

Limited Liability Company «BEBIG», Moscow, Russia

Kaprin D.A.

Department of Surgery, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia

Moroz O.V.

Faculty of fundamental medicine, Moscow State University

Cherednichenko D.V.

Joint Stock Company «RusAtom Healthcare», Moscow, Russia

Dobreva I.Yu.

Joint Stock Company «RusAtom Healthcare», Moscow, Russia

Polushkin V.G.

Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet imeni N.I. Pirogova;
Gorodskaia klinicheskaia bol'nitsa #31, Moskva

Khodovsky A.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Therapy for inoperable hepatocellular carcinoma with selective transarterial radioembolization with yttrium-90 microspheres

Authors:

Liadov K.V., Kaprin A.D., Rerberg A.G., Kozyrin I.A., Lyadov V.K., Maiorov K.V., Kaprin D.A., Moroz O.V., Cherednichenko D.V., Dobreva I.Yu., Polushkin V.G., Khodovsky A.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2018;7(3): 55‑60

DOI: 10.17116/onkolog20187355

Views: 3400

Downloaded: 136

Download PDF (RU)
Contact the author
Table of contents

THERAPY FOR INOPERABLE HEPATOCELLULAR CARCINOMA WITH SELECTIVE TRANSARTERIAL RADIOEMBOLIZATION WITH YTTRIUM-90 MICROSPHERES
THERAPY FOR INOPERABLE HEPATOCELLULAR CARCINOMA WITH SELECTIVE TRANSARTERIAL RADIOEMBOLIZATION WITH YTTRIUM-90 MICROSPHERES

To cite this article:

Liadov KV, Kaprin AD, Rerberg AG, et al. . Therapy for inoperable hepatocellular carcinoma with selective transarterial radioembolization with yttrium-90 microspheres. P.A. Herzen Journal of Oncology. 2018;7(3):55‑60. (In Russ.)
https://doi.org/10.17116/onkolog20187355

Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Hepa­tocellular carcinoma asso­ciated with nona­lcoholic fatty liver disease. P.A. Herzen Journal of Onco­logy. 2024;(6):57-62

Hepatocellular carcinoma is generally diagnosed at a late stage, which makes surgical treatment difficult. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, patients with inoperable tumors can undergo transarterial chemoembolization or palliative therapy with sorafenib, their response rate does not exceed 30%. At the same time, the results of transarterial radioembolization (TARE) using yttrium-90-containing microspheres demonstrate an optimistic picture. In this paper, the authors systematize from expert positions the current data from the literature on the use of TARE to treat liver cancer in clinical practice and formulate prospects for using the technique in the Russian Federation. Based on the literature data, the authors demonstrate the superiority of TARE over sorafenib therapy and the results that are comparable with chemoembolization.

Keywords:

hepatocellular carcinoma
transarterial embolization
radioembolization

Authors:

Liadov K.V.

Lechebno-reabilitatsionnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Rerberg A.G.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kozyrin I.A.

Klinika khirurgii i onkologii Lechebno-reabilitatsionnogo tsentra Minzdrava RF, Moskva

Lyadov V.K.

Medical and Rehabilitation Center under the Ministry of Health of Russian Federation, Moscow, Russia

Maiorov K.V.

Limited Liability Company «BEBIG», Moscow, Russia

Kaprin D.A.

Department of Surgery, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia

Moroz O.V.

Faculty of fundamental medicine, Moscow State University

Cherednichenko D.V.

Joint Stock Company «RusAtom Healthcare», Moscow, Russia

Dobreva I.Yu.

Joint Stock Company «RusAtom Healthcare», Moscow, Russia

Polushkin V.G.

Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet imeni N.I. Pirogova;
Gorodskaia klinicheskaia bol'nitsa #31, Moskva

Khodovsky A.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

List of references:

  1. Kaprin AD, Starinskii VV, Petrova GV, eds. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow: MNIOI im. P.A. Gertsena — filial FGBU NMIRTs Minzdrava Rossii; 2017. (In Russ.)
  2. Bazin IS, Breder VV, Virshke ER, Gorbunova VA, Dolgushin BI, Kosyrev VYu, Kukushkin AV, Makarov ES, Moroz E.A, Nechushkin M, Patyutko YuI, Polyakov AN, Sagaidak IV, Sergeeva ON, Fainshtein IA. Clinical recommendations for the diagnosis and treatment of patients with liver cancer and extra hepatic bile ducts. Moscow: Obshcherossiiskii soyuz obshchestvennykh ob'dinenii, Assotsiatsiya onkologov Rossii; 2014. (In Russ.)
  3. Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35(3):1036-1047. https://doi.org/10.1111/liv.12574
  4. Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, Bae SH, Kim do Y, Heo J, Kim YJ. Radioembolization is a safe and effective treatment for Hhpatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS One. 2016;11(5):e0154986. https://doi.org/10.1371/journal.pone.0154986
  5. Shapovalov VV, Mel’nichenko NA, Nerozin NA, Tkachev SV, Togaeva NR, Kham’yanov SV. Extraction-chromatographic isolation of 90Y for medical purposes. Radiokhimiya. 2012;54(4):357-359. (In Russ.) https://doi.org/10.1134/s1066362212040133
  6. Asakura H. Intratumoral injection therapy with Yttrium-90 chloride colloid. Nihon Igaku Hoshasen Gakkai Zasshi. 1964;23:1493-1509.
  7. Grady ED, Nolan TR, Crumbley AJ, Rosen AR. Internal radiation therapy of liver cancer (90-Yttrium resin spheres intra-arterially) to supplement external radiation therapy, local and systemic chemotherapy. J Med Assoc Ga. 1977;66(8):625-629.
  8. Tong A, Kao Y, Too C, Chin K, Ng D, Chow P. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89(1062):20150943. https://doi.org/10.1259/bjr.20150943
  9. Ahmadzadehfar H, Duan H, Haug A, Walrand S, Hoffmann M. The role of SPECT/CT in radioembolization of liver tumours. Eur J Nucl Med Mol Imaging. 2014;41(Suppl.1):S115-S124. https://doi.org/10.1007/s00259-013-2675-5
  10. Gallio E, Richetta E, Finessi M, Stasi M, Pellerito R, Bisi G, Ropolo R. Calculation of tumour and normal tissue biological effective dose in 90 Y liver radioembolization with different dosimetric methods. Phys Med. 2016;32(12):1738-1744. https://doi.org/10.1016/j.ejmp.2016.10.023
  11. Kokabi N, Camacho J, Xing M, El-Rayes B, Spivey J, Knechtle S, Kim H. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Cancer. 2015;121(13):2164-2174. https://doi.org/10.1002/cncr.29275
  12. Kim D, Park B, Kim Y, Han K, Cho S, Cho K, Uhm S, Choe J, Choi J, Chun H, Lee H, Gwon D, Lee K, Yoon J, Chung J, Kim C, Heo J, Kim J, Joo Y. Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma. Am J Clin Oncol. 2015;38(5):495-501. https://doi.org/10.1097/coc.0b013e3182a78dba
  13. Fidelman N, Kerlan R, Hawkins R, Taylor A, Kohi M, Kolli K, Bergsland E, Kelley R, Ko A, Korn W, McWhirter R, Luan J, Venook A. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014;45(2):168-180. https://doi.org/10.1007/s12029-013-9566-7
  14. Biederman D, Titano J, Tabori N, Pierobon E, Alshebeeb K, Schwartz M, Facciuto M, Gunasekaran G, Florman S, Fischman A, Patel R, Nowakowski, F, Kim E. Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres. J Vasc Intervent Radiol. 2016;27(6):812-821. e2. https://doi.org/10.1016/j.jvir.2016.01.147
  15. Merkulov VG, Khabas TA, Kulinich EA. Radioactive sources of medical assignment based on bioinert ceramic materials. Izvestiya vysshikh uchebnykh zavedenii. Fizika. 2010;53(10-2):329-333. (In Russ.)
  16. Antroshchenko GN, Sigaev VN. Glassy microspheres and their applications in nuclear medicine (Review). Steklo i keramika. 2015;11:3-12. (In Russ.) https://doi.org/10.1007/s10717-016-9797-8
  17. Tarazov PG, Polikarpov AA, Ivanova AA. Arterial radioembolization of liver malignancies with Yttrium-90 glass microspheres: first experience. Diagnosticheskaya i interventsionnaya radiologiya. 2014;8:59-66. (In Russ.)
  18. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-1163. e2. https://doi.org/10.1053/j.gastro.2016.08.029
  19. Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and metaanalysis. Cardiovasc Intervent Radiol. 2016;39(11):1580-1588. https://doi.org/10.1007/s00270-016-1426-y
  20. Edeline J, Crouzet L, Campillo-Gimenez B, Rolland Y, Pracht M, Guillygomarc’h A, Boudjema K, Lenoir L, Adhoute X, Rohou T, Boucher E, Clément B, Blanc J, Garin E. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging. 2015;43(4):635-643. https://doi.org/10.1007/s00259-015-3210-7
  21. Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2016;(2):CD011313. https://doi.org/10.1002/14651858.cd011313.pub2
  22. Zhang Y, Li Y, Ji H, Zhao X, Lu H.Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a metaanalysis. Biosci Trends. 2015;9(5):289-298. https://doi.org/10.5582/bst.2015.01089
  23. Kolligs F, Bilbao J, Jakobs T, Iñarrairaegui M, Nagel J, Rodriguez M, Haug A, D’Avola D, op den Winkel M, Martinez-Cuesta A, Trumm C, Benito A, Tatsch K, Zech C, Hoffmann R, Sangro B. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715-1721. https://doi.org/10.1111/liv.12750
  24. Abuodeh Y, Naghavi A, Ahmed K, Venkat P, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya D, Kim R, Malafa M, Frakes J, Hoffe S, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol. 2016;22(47):10406-10414. https://doi.org/10.3748/wjg.v22.i47.10406
  25. Ozkan Z, Poyanli A, Ucar A, Kuyumcu S, Akyuz F, Keskin S, Saglam S, Yilmaz E, Karaca C, Turkmen C. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Cancer Biother Radiopharmaceut. 2015;30(3):132-138. https://doi.org/10.1089/cbr.2014.1748
  26. Lewandowski R, Andreoli J, Hickey R, Kallini J, Gabr A, Baker T, Kircher S, Salem R, Kulik L. Angiogenic response following radioembolization: results from a randomized pilot study of Yttrium-90 with or without Sorafenib. J Vasc Intervent Radiol. 2016;27(9):1329-1336. https://doi.org/10.1016/j.jvir.2016.03.043
  27. Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, Garin E. Gemcitabine and oxaliplatin, but not sorafenib or paclitaxel, have a synergistic effect with Yttrium-90 in reducing hepatocellular carcinoma and cholangiocarcinoma cell line viability. J Vasc Intervent Radiol. 2015;26(12):1874-1878. e2. https://doi.org/10.1016/j.jvir.2015.06.032
  28. Johnson G, Monsky W, Valji K, Hippe D, Padia S. Yttrium-90 radioembolization as a salvage treatment following chemoembolization for hepatocellular carcinoma. J Vasc Intervent Radiol. 2016;27(8):1123-1129. https://doi.org/10.1016/j.jvir.2016.03.046
  29. Qin X, Jia Z, Jiang G, Tian F, Zhu C. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol. 2016;22(5):353-359. https://doi.org/10.4103/1319-3767.191139
  30. Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2015;43(3):559-575. https://doi.org/10.1007/s00259-015-3157-8
  31. Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P, Denys A, Prior J, Baechler S, Boubaker A. Partition model-based 99mTc-MAA SPECT/CT predictive dosimetry compared with 90Y TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57(11):1672-1678. https://doi.org/10.2967/jnumed.116.173104
  32. BishayV, Biederman D, Ward T, van der Bom I, Patel R, Kim E, Nowakowski F, Lookstein R, Fischman A. Transradial approach for hepatic radioembolization: ibnitial results and technique. Am J Roentgenol. 2016;207(5):1112-1121. https://doi.org/10.2214/ajr.15.15615
  33. Forner A, Reig M, Rodriguez de Lope C, Bruix J. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61-74. https://doi.org/10.1055/s-0030-1247133
  34. Fidelman N, Kerlan R Jr, Hawkins R, Pampaloni M, Taylor A, Kohi M, Kolli K, Atreya C, Bergsland E, Kelley R, Ko A, Korn W, Van Loon K, McWhirter R, Luan J, Johanson C, Venook A. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016;7(6):860-874. https://doi.org/10.21037/jgo.2016.08.04
  35. Abbott A, Kim R, Hoffe S, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith K, Almhanna K, Strosberg J, Shibata D, Fulp W, Shridhar R. Outcomes of therasphere radioembolization for colorectal metastases. Clin Colorectal Cancer. 2015;14(3):146-153. https://doi.org/10.1016/j.clcc.2015.02.002
  36. Gruber-Rouh T, Naguib NN, Eichler K, Ackermann H, Zangos S, Trojan J, Beeres M, Harth M, Schulz B, Nour-Eldin A NE, Vogl TJ. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. Int J Cancer. 2013;134(5):1225-1231. https://doi.org/10.1002/ijc.28443
  37. Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F; Italian Society of Locoregional Therapies in Oncology (SITILO). Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103(3):324-331. https://doi.org/10.1038/sj.bjc.6605770
  38. Krishnan S, Lin EH, Gunn GB, Chandra A, Beddar AS, Briere TM, Das P, Delclos ME, Janjan NA, Crane CH. Conformal radiotherapy of the dominant liver metastasis. Am J Clin Oncol. 2006;29(6):562-567. https://doi.org/10.1097/01.coc.0000236210.41199.91
  39. Khitar’yan AG, Glumov EE, Miziev IA, Prazdnikov EN, Murlychev AS, Kovalev SA, Provorotov ME,Voronova OV. Morphological substantiation of tactics of conducting the embolization microspheres HepaSphereTM arteries supplying hollow organs.Vestnik khirurgicheskoi gastroenterologii. 2015;3-4:46-53. (In Russ.)
  40. Chong H, Sun X, Chen Y, Sin I, Kang C, Lewis M, Liu D, Ruthengael V, Zhong Y, Wu N, Song H. Synthesis and comparative biological evaluation of bifunctional ligands for radiotherapy applications of 90Y and 177Lu. Bioorg Med Chem. 2015;23(5):1169-1178. https://doi.org/10.1016/j.bmc.2014.12.035
  41. Hashikin N, Yeong C, Abdullah B, Ng K, Chung L, Dahalan R, Perkins A. Neutron activated Samarium-153 microparticles for transarterial radioembolization of liver tumour with post-procedure imaging capabilities. PLoS One. 2015;10(9):e0138106. https://doi.org/10.1371/journal.pone.0138106

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.